2Wolf G, Chen S,Ziyadeh FN. From the periphery of the glomemlar capil- lary wall toward the center of disease :podocyte injury comes of age in di- abetic nephropathy[ J]. Diabetes,2005,54(6) : 1626 - 1634.
3Zhang Q,Kelly AP,Wang L,et al. Green tea exact and ( - )-epigallo- catechin-3-gallate inhibit mast cell-stimulated type I collagen expressionin keloid fibroblasts via blocking PI-3K/AkT signaling pathways [ J ]. J Invest Derrnatol,2006,126 (12) :2607 - 2613.
4Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin amehorates proteinuria- associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy [ J ]. J Am Soc Nephro1,2005,16 (7) : 2063.
5Alperovich G, Rama I, Lloberas N, et al. New immunosuppresor strategies in the treatment of murine lupus nephritis I J]. Lupus,2007, 16 (1): 18 - 24.
6Ramos-Barr6n A, Pinera-Haces C, G6mez-Alamillo C, et al. Prevention of routine lupus disease in (NZBxNZW) F1 mice by sirolimus treatment [ J ]. Lupus,2007,16 (10) :775 - 781.
7Laplante M, Sabatini DM. mTOR signaling at a glance [ J ]. J Cell Sci, 2009,122 ( Pt 20) :3589 - 3594.
9Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glo- merulosclerosis is associated with nephrotoxicity [ J ]. Am J Kidney Dis, 2007, 49(2) :310 -317.
二级参考文献11
1Rosner D, McCarthy N, Bennett M. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phos- phorylation and p53 [J]. Cardiovasc Res, 2005 (66):601-610.
2Rhoads JM, Niu X, Odle J,et al. Role of mTOR signaling in intestinal cell migration[J]. Am J Physiol Gastrointest Liver Physiol, 2006(291): G510-517.
3Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive [J]. Nat Cell Biol, 2004(6): 1122-1128.
4Steffel J, Latini RA, Akhmedov A, et al. Tanner. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design[J]. Circulation,2005(112):2002-2011.
5Laplante M Sabatini, DM. mTOR signaling at a glance [J]. J Cell Sci, 2009(122):3589-3594.
6Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpoly- mer-based rapamycin-eluting stent versus a polymer-based paclitaxel- eluting stent for the reduction of late lumen loss[J]. Circulation, 2006 (113):273-279.
7Marx SO, Marks AR. Bench to bedside: the development ofrapamycin and its application to stent restenosis [J]. Circulation, 2001 (104): 852-855.
8Villaume K, Blanc M, Gouysse G, et al. VEGF secretion by neuroen- docrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway [J]. Neuroendocrinology, 2010 (91): 268-278.
9Frost P, Shi Y, Hoang B, et al. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells[J]. Oncogene, 2007(26):2255-2262.
10Kanno S, Oda N, Abe M, et al. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascu- lar endothelial cells[J]. Oncogene,2000(29):2138-2146.
7Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long -term trial of tacrolimus/sirolimus versus tacrolimus/my- cophenolate mofetil versus cyclosporine (NEORAL)/ sirolimusin renal transplantation. 11. Survival, function, and protocol compliance at 1 year. Transplantation, 2004 ; 77 C2) :252-258.
8Reis A, Megahed M, Reinhard T, et al. Synergism of rad and cyclosporine A in prevention of acute rat corneal allograft rejection [ J ]. Cornea ,2002 ;21 ( 1 ) :81-84.
9Reis A, Megahed M, Reinhard T, et al. Rad, A new immunosup- pressive macrolide in murine corneal transplantation [ J ]. Graefes Arch Clin Exp Ophthalmol, 2001 ;239(9) :689-692.
